We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Research on Amrubicin Monotherapy to Treat Advanced Non-Small Cell Lung Cancer.
- Authors
Yoshitsugu Fujita; Masamichi Mineshita; Naoki Furuya; Hirotaka Kida; Hiroshi Handa; Fuzuki Ishikawa; Hiroki Nishine; Miho Nakamura; Masahiro Oshige; Junko Saji; Atsuko Ishida; Seichi Nobuyama; Takeo Inoue; Taeko Shirakawa; Teruomi Miyazawa; Kenji Eguchi; Nobuhiko Seki; Inoue, Ken
- Abstract
Introduction, and Materials and Methods: There is currently no clear evidence on what treatments should constitute tertiary and subsequent treatments for advanced non-small cell lung cancer (NSCLC). Amrubicin monotherapy has recently been studied as a treatment for NSCLC and may represent a potential regimen for tertiary and subsequent treatments. This report summarizes 7 cases in which amrubicin monotherapy was used to treat advanced NSCLC. Results and Conclusion: In cases where "neutropenia" was noted, corresponding to grade 3 to 4 hematological toxicity, the patient's neutrophil count recovered with the administration of G-CSF, and amrubicin monotherapy was safely continued. This study will be continued in the future on a larger scale and in greater detail.
- Subjects
NEUTROPENIA; ANALYSIS of variance; ANTINEOPLASTIC agents; LUNG cancer; CASE studies; DISEASE risk factors
- Publication
International Medical Journal, 2011, Vol 18, Issue 2, p145
- ISSN
1341-2051
- Publication type
Article